Hospital Acquired Infections Diagnostics Market: Understanding Key Segments and Growth Prospects
Author : Manisha S | Published On : 26 Oct 2026
The global Hospital Acquired Infections Diagnostics Market is driven by the increasing need for early infection detection, growing antimicrobial resistance, and the rising focus on patient safety across healthcare facilities. Hospital-acquired infections (HAIs), also known as healthcare-associated infections, develop during medical treatment in hospitals and other healthcare settings. These infections can lead to severe complications, prolonged hospital stays, higher treatment costs, and increased mortality, making accurate and timely diagnosis essential for effective infection management.
According to Grand View Research, the global hospital acquired infections diagnostics market was valued at USD 4.3 billion in 2024. The market is projected to grow from USD 4.5 billion in 2026 to USD 4.7 billion by 2030, registering a CAGR of 1.5% from 2025 to 2030. The industry is supported by the increasing incidence of healthcare-associated infections, the emergence of drug-resistant pathogens, and technological advancements that improve diagnostic accuracy and turnaround time.
Key Factors Driving Market Growth
Increasing Prevalence of Hospital-Acquired Infections
Hospital-acquired infections remain a significant challenge for healthcare systems worldwide. Patients undergoing surgery, receiving intensive care, using urinary catheters, or requiring mechanical ventilation may face a greater risk of infection. Common HAIs include urinary tract infections, surgical-site infections, bloodstream infections, and hospital-acquired pneumonia.
The increasing number of complex medical procedures and the growing population of older adults contribute to demand for dependable diagnostic testing. Early identification allows healthcare professionals to initiate appropriate treatment and implement measures to limit the spread of pathogens within healthcare facilities.
Diagnostic testing also supports hospital surveillance programs by helping healthcare teams monitor infection patterns and identify potential outbreaks. As healthcare providers prioritize patient safety and quality of care, reliable HAI diagnostic solutions remain an important part of clinical practice.
Growing Antimicrobial Resistance
Antimicrobial resistance is another important factor influencing the hospital acquired infections diagnostics market. Certain pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile, can complicate infection management and increase the need for accurate diagnostic evaluation.
When infections are caused by drug-resistant microorganisms, identifying the pathogen and understanding its susceptibility to available treatments become especially important. Diagnostic methods that provide timely results can help clinicians make more informed treatment decisions and support antimicrobial stewardship initiatives.
Hospitals are increasingly interested in diagnostic platforms that combine pathogen identification with resistance-related information. These capabilities can help reduce delays in treatment selection and support efforts to minimize inappropriate antibiotic use.
Go Deeper! Ask Prism AI
about the Global Hospital Acquired Infections Diagnostics Market. Get instant answers to
questions related to market sizing, growth drivers & their impact, and more.
Market Segmentation and Emerging Trends
1. Test Insights: Conventional and Molecular Diagnostics
The market is segmented into conventional and molecular tests. Conventional diagnostic methods maintained the leading position in 2024 because of their established role, affordability, and broad use across clinical laboratories. These methods include culture-based testing, microscopy, and biochemical techniques for identifying microorganisms responsible for infections.
2. Infection Insights: Urinary Tract Infections and Pneumonia
Urinary tract infections represented the largest infection category in the hospital acquired infections diagnostics market in 2024. Catheter-associated urinary tract infections are a particular concern because urinary catheters can provide a route for microorganisms to enter the urinary tract.
3. Product Insights: Consumables and Instruments
Consumables held the largest revenue share in 2024 and are expected to record the fastest growth among product categories. These products include reagents, test kits, assay components, and other materials required for routine diagnostic procedures.
4. Type Insights: Blood Tests and Urinalysis
Blood tests represented the largest segment by revenue in 2024 and are expected to register a CAGR of 1.55% during the forecast period. These tests are essential for evaluating suspected bloodstream infections and identifying potential indicators of serious systemic infections, including sepsis.
Looking for more specific insights? Customize this report to suite your business needs
Regional Outlook: North America, Europe, and Asia Pacific
Regional market performance reflects differences in healthcare infrastructure, diagnostic access, infection-control policies, and the adoption of advanced technologies.
North America remains an important market because of its established healthcare infrastructure, diagnostic capabilities, and focus on infection prevention. Hospitals in the region continue to invest in technologies that support pathogen detection, antimicrobial resistance monitoring, and clinical laboratory efficiency.
Europe accounted for the largest regional revenue share in 2024, representing 34.57% of the global market. The region benefits from developed healthcare infrastructure, substantial healthcare expenditure, technological innovation, government initiatives, and established diagnostic companies. Investment in molecular testing and digital diagnostic solutions also supports regional demand.
Asia Pacific is expected to register the fastest regional growth, with a projected CAGR of 2.29% from 2025 to 2030. Growing healthcare expenditure, increasing demand for cost-effective diagnostic solutions, and expanding access to laboratory services are contributing to this outlook. The increasing focus on infection surveillance in countries such as India and China may further support market development.
Competitive Landscape and Recent Developments
The hospital acquired infections diagnostics market includes established healthcare and life sciences companies developing diagnostic instruments, reagents, molecular assays, and integrated laboratory solutions.
Key companies profiled by Grand View Research include:
• bioMérieux
• Abbott
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare Private Limited
• Becton, Dickinson and Company
• Hologic, Inc.
• Meridian Bioscience, Inc.
• QIAGEN
• Thermo Fisher Scientific Inc.
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
Explore U.S. Healthcare Facility Mapping & Intelligence Platform - https://www.grandviewresearch.com/horizon/hospital-database
